Investors
Investera i framtidens hälsoteknik – delta i Attanas emission
Attana banar väg för individanpassade immunitetstest med en unik teknologi som simulerar kroppens miljö. Delta i emissionen och bli en del av vår resa.
Events & presentations
Stora Aktiedagen 2025
CEO Anna Hellergård presents at Stora Aktiedagarna in Stockholm – 27 november 2025
Redeye Theme Event Medtech & Diagnostics
CEO Anna Hellergård presents at Redeye Theme Event Medtech & Diagnostics – November 12
Redeye Medtech 2025
At the event, CEO Anna Hellergård presented Attana’s unique QCM technology, emphasizing real-time measurement of molecular interactions without labeling. She outlined the company’s two business areas, recent progress, and focus on scalable growth, commercialization, and the upcoming TO2 in May/June 2025.
Aktiespararna Life Science Day 2025
Presentation by CEO Anna Hellergård (2025-04-23)
At the event, CEO Anna Hellergård highlighted Attana’s unique QCM technology and its ability to measure molecular interactions in real-time within complex biological environments—without labeling or purification.The presentation covered Attana’s two business areas, recent scientific and commercial progress, and the company’s focus on scalable growth, increased commercialization, and upcoming TO2 in May/June 2025.
Småbolagsdagarna 2022
Our presentation at Aktiespararna’s “Småbolagsdagarna” (2022-06-14)
CEO Teodor presented our two business areas, Attana Life Science and Attana Diagnostics and focus on both the short- and long-term plans going forward.
Erik Penser Bank Bolagsdag 2022
CEO Teodor Aastrup’s presentation at Erik Penser Bank’s Bolagsdag (2022-03-10).
An introduction to Attana, our track record within Life Science and an update on our patent portfolio.
Investera i framtidens hälsoteknik – delta i nyemissionen
Attana banar väg för individanpassade immunitetstest med en unik teknologi som simulerar kroppens miljö. Delta i nyemissionen och bli en del av vår resa.
Financial information
Financial reports & calendar
External financial reports
2026-02-27 – Bokslutskommuniké 2025
2026-04-30 – Årsredovisning 2025
2026-05-13 – Årsstämma
2026-05-29 – Delårsrapport Q1 2026
2025-02-28 – Bokslutskommuniké 2024
2025-04-22 – Årsredovisning 2024
2025-05-20 – Delårsrapport Q1 2025
2025-05-20 – Signerad årsredovisning med revisionsberättelse
2024-02-23 – Bokslutskommuniké 2024
2024-04-19 – Årsredovisning 2023
2024-05-02 – Årsredovisning 2023 – Revisionsberättelse
2024-05-03 – Delårsrapport Q1 2024 (januari-mars)
2023-02-24 – Bokslutskommuniké 2022
2023-05-04 – Årsredovisning 2022
2023-05-04 – Årsredovisning 2022 – Revisionsberättelse
2023-05-05 – Delårsrapport Q1 2023 (jan-mar)
Memorandums & offerings
2022-12-08 – Så här gör du för att teckna aktier i Attana
2018-03-07 – Första handelsdag på NGM
Stock information
Investor relations
Anna Hellergård – CEO
Phone: +46 70 886 23 06
Email: ir@attana.com
News & press
Attana’s press announcements and news are published via Cision. Attana communicates in Swedish or English. Attana AB is required under the Swedish Securities Market Act to disclose certain information and such information is primarily provided in Swedish on the Swedish news room.
Information related to scientific publications from the company’s customers is primarily provided in English on the English news room.
If you wish to receive all information from Attana we recommend that you subscribe for news written in Swedish and English by visiting the news rooms.
Corporate governance
General meetings
› Attana – Styrelsens redogörelse 13.6 (FSEN 250612)
› Bilaga 3 – Revisorns yttrande 13.6 (signerat)
2024-10-31 – Kallelse till extra bolagstämma
› Fullmaktsformulär
› Bilaga 1 – Styrelsens redogörelse
› Bilaga 2 – Revisorns yttrande
› Bilaga 3 – Beslut om företrädesemission
› Bilaga 3A – Fullständiga villkor för teckningsoptioner av serie TO 2
› Bilaga 3B – Fullständiga villkor för teckningsoptioner av serie TO 3
› Föreslagen ny bolagsordning
Other company documents
Board of Directors
Arne Nabseth (b. 1963)
Chairman since 2015
25 years of experience in the IT industry. Entrepreneurial experience from building PCM Nordic/MAS, Applicon and Qrodo. Previously venture capitalist at Ledstiernan, IT manager at Philips Electronics, KPMG, Bearing Point Silicon Valley and an angel investor.
Lena Jendeberg (b. 1964)
Director since 2018
PhD from KTH Royal Institute of Technology with 25+ years of experience in the pharmaceutical industry working at Pharmacia, Biovitrum, Sobi, Modus Therapeutics and Wilson Therapeutics. Have developed pharmaceuticals all the way from the pre-clinical phase to improvement of approved products.
Rolf Lundh
M.D, PhD Karolinska Institute Stockholm
More than 30 years experience from Senior managerial global positions in pharmaceutical research (10 years with Astra and 13 years with the Pharmacia Corporation.